Psychological Treatment for Depressive Disorder

被引:2
|
作者
Li, Xiaobai [1 ]
Wang, Qi [1 ]
机构
[1] China Med Univ, Hosp 1, Dept Psychiat, Shenyang, Peoples R China
关键词
Depression; Psychotherapy; Antidepressants; COGNITIVE-BEHAVIORAL THERAPY; PROBLEM-SOLVING THERAPY; RANDOMIZED CONTROLLED-TRIAL; BRIEF INTERPERSONAL PSYCHOTHERAPY; LATE-LIFE DEPRESSION; MAJOR DEPRESSION; ADULT DEPRESSION; OLDER-ADULTS; SUICIDAL IDEATION; ANTIDEPRESSANT TREATMENT;
D O I
10.1007/978-981-32-9271-0_13
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Depression is highly prevalent and causes unnecessary human suffering and economic loss. Therefore, its treatment and prevention are of utmost importance. There are several advantages of using psychotherapy either by itself or combined with pharmacological treatment methods in the treatment of depression. First, it is well known that combining biological treatment with psychosocial methods increases the chances of recovery. Second, in some individuals, psychotherapy continues to be the only solution. Third, the use of antidepressants contains some safety risks and side effects, but psychotherapy does not. Fourth, clinically, depressive patients prefer psychotherapy to drug therapy. Use of a depression-focused psychotherapy alone is recommended as an initial treatment choice for patients with mild to moderate depression, with clinical evidence supporting the use of cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), psychodynamic psychotherapy (PDP), and problem-solving therapy (PST) in individual and group formats. Important developments took place within the past 20 years in the psychotherapy of depression. In the present chapter, we introduced several key issues, such as, Are all psychotherapies equally effective? Who benefits from psychotherapies? Is telepsychotherapy effective? Finally, we introduce the psychotherapy for special populations.
引用
收藏
页码:233 / 265
页数:33
相关论文
共 50 条
  • [31] Agomelatine Treatment of Major Depressive Disorder
    Dolder, Christian R.
    Nelson, Michael
    Snider, Morgan
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (12) : 1822 - 1831
  • [32] Individualized Treatment Strategy for Depressive Disorder
    Chen, Jun
    Hu, Shaohua
    DEPRESSIVE DISORDERS: MECHANISMS, MEASUREMENT AND MANAGEMENT, 2019, 1180 : 219 - 232
  • [33] Vortioxetine in the treatment of major depressive disorder
    Baldwin, David S.
    Hanumanthaiah, Venkatesh Ballagere
    FUTURE NEUROLOGY, 2015, 10 (02) : 79 - 89
  • [34] Optimized Treatment Strategy for Depressive Disorder
    Chen, Peijun
    DEPRESSIVE DISORDERS: MECHANISMS, MEASUREMENT AND MANAGEMENT, 2019, 1180 : 201 - 217
  • [35] Diagnosis and Treatment of Major Depressive Disorder
    Soleimani, Laili
    Lapidus, Kyle A. B.
    Iosifescu, Dan V.
    NEUROLOGIC CLINICS, 2011, 29 (01) : 177 - +
  • [36] Vilazodone for the Treatment of Major Depressive Disorder
    Iranikhah, Maryam
    Wensel, Terri M.
    Thomason, Angela R.
    PHARMACOTHERAPY, 2012, 32 (10): : 958 - 965
  • [37] Desvenlafaxine in the treatment of major depressive disorder
    Lourenco, Maria Teresa C.
    Kennedy, Sidney H.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2009, 5 : 127 - 136
  • [38] Desvenlafaxine for the treatment of major depressive disorder
    Kornstein, Susan G.
    McIntyre, Roger S.
    Thase, Michael E.
    Boucher, Matthieu
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1449 - 1463
  • [39] Treatment of major depressive disorder in epilepsy
    Radmanovic, B.
    Dejanovic, S. Djukic
    Ravanic, D.
    Mihajlovic, G.
    Pantovic, M.
    Janjic, V.
    Jovanovic, M.
    Radmanovic, O.
    Ilic, M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 154 - 154
  • [40] Desvenlafaxine in the treatment of major depressive disorder
    Pae, Chi-Un
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) : 2923 - 2928